The Corporate Executive Committee is responsible for managing Bachem worldwide and for implementing policies and strategies as defined by the Board of Directors.
Chief Executive Officer (CEO)
Chief Financial Officer (CFO)
Alain Schaffter started his career as an auditor at PricewaterhouseCoopers. In 2010, he moved into the pharmaceutical industry and became Head Group Finance of the listed Acino Group before joining Polyphor, a Basel-based biotech company, as CFO in 2016.
In early 2018, he started to work as a consultant for several companies in the Life Science Industry, supporting them in specific projects like Reporting, IFRS conversion or IPO preparation before he became Head Special Finance Projects at Solvias AG in August 2018. There he ran and coordinated the due diligence and deal related activities for the sale of Solvias Group to two Healthcare Investors, including process optimization in the areas of Accounting, Tax and Reporting. After completion of the transaction in June 2020, Alain Schaffter assumed, in addition to his existing role, the role as Head Finance M&A but also as CFO on an ad interim basis.
He served also as a Member of Group Executive Committees and held various mandates as Chairman of the Board of Trustees and as a member of the Board of Directors, of the Management Board and of the Audit Committee at subsidiaries worldwide.
Alain Schaffter holds a degree as a Swiss certified public accountant as well as a Federal certificate of higher vocational education and training for fiduciaries.
Chief Technology Officer (CTO)
Guenther Loidl joined Bachem in 2000. He held several functions in Research and Development (R&D) and Active Pharmaceutical Ingredient Manufacturing and became Vice President R&D in 2012. Since 2015, he is CTO of the Bachem Group and a member of the Corporate Executive Committee.
He studied chemistry in Regensburg (Germany) and Leeds (UK) and obtained his doctorate under the supervision of Prof. Dr. Luis Moroder at the Max Planck Institute of Biochemistry in Martinsried (Germany).
He drives building the oligonucleotide business segment and is leading the Bachem innovation initiative.
Chief Commercial Officer (CCO)
Torsten Wöhr joined Bachem in 2017 as Sales Director for the generic API business and has led Bachem’s oligonucleotide program since 2019.
Previously he held commercial leadership roles in various pharmaceutical manufacturing and life sciences companies in the United States and Europe.
He studied biochemistry & molecular biology at the Swiss Federal Institute of Technology (ETH) Zurich and holds a doctorate in bioorganic chemistry from the University of Lausanne/EPFL and a postgraduate degree in Industrial Engineering and Management, ETH Zurich.
Chief Operations Officer (COO)
Roland Schürmann joined Bachem Americas, Inc. in Torrance, California in 2016. He was first Vice President Manufacturing and became Site Manager Torrance in May 2017. Roland Schürmann was appointed COO of the Bachem Group and member of the Corporate Executive Committee effective July 1, 2020. After completing his education, he worked as a chemical laboratory technician at Ciba-Geigy AG and as a production chemist at F. Hoffmann-La Roche Ltd from 1984 to 1997. After holding various management positions at Siegfried AG in Zofingen, Switzerland, Roland Schürmann became Head of Chemical Production in 2004. Parallel to working, he was a senior lecturer for Chemical Technology from 1999 to 2015 at the vocational college in Aarau.
Roland Schürmann has a university of applied sciences degree in chemistry from the School of Engineering Burgdorf and is currently completing the Advanced Management Program at INSEAD Business School, Fontainebleau/Paris.
Board of Directors
The Board of Directors are responsible for defining Bachem’s corporate strategy and are elected by the company shareholders.
Click here >>
Our passionate and dedicated employees, along with our unique corporate culture are the foundation of our success.
Click here >>